BFM
ADVM

Boothbay Fund Management’s Adverum Biotechnologies ADVM Stock Holding History

Boothbay Fund Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-29
Closed -$295K – 1213
2020
Q3 		$295K Buy
+29
New +$4.34K 0.02% 809

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Boothbay Fund Management's ADVM Position: Q4 2018 in Review

Boothbay Fund Management sold out of Adverum Biotechnologies (ADVM) in Q4 2018, closing a stake of 2,586 shares — an estimated $156K sold.

Boothbay Fund Management first reported a position in ADVM in Q4 2017 and held it in 4 quarters. The position peaked at $772K in Q1 2018. 86 funds tracked by Wall St. Rank hold ADVM as of Q4 2018.

  • Boothbay Fund Management reported no remaining Adverum Biotechnologies position as of Q4 2018 after selling out during the quarter.
  • Boothbay Fund Management sold 2,586 Adverum Biotechnologies shares in Q4 2018, an estimated $156K.
  • Boothbay Fund Management first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 4 quarters.
  • Boothbay Fund Management's Adverum Biotechnologies position peaked at $772K in Q1 2018.
  • 86 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2018.

Based on Boothbay Fund Management's 13F filing for Q4 2018, filed 14 Feb 2019.